Hirashima, Tomonori
Tamura, Yoshitaka
Han, Yuki
Hashimoto, Shoji
Tanaka, Ayako
Shiroyama, Takayuki
Morishita, Naoko
Suzuki, Hidekazu
Okamoto, Norio
Akada, Shinobu
Fujishima, Makoto
Kadota, Yoshihisa
Sakata, Kazuya
Nishitani, Akiko
Miyazaki, Satoru
Nagai, Takayuki
Article History
Received: 19 August 2017
Accepted: 2 October 2018
First Online: 12 October 2018
Ethics approval and consent to participate
: Ethics and publication of this study was approved by the Institutional Review Board of the Osaka Habikino Medical Center (formerly the Osaka Prefectural Medical Center for Respiratory and Allergic Diseases) (Osaka, Japan) on January 30, 2017 (approval no.: 808–1). The board waived the requirement for informed written consent due to the anonymous nature of the data and the fact that this research presented no risk of exposure to the subjects. Research was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.
: Not applicable.
: T.H. has received honoraria and research funding from Ono Pharmaceutical Co. Ltd. (Osaka, Japan), Lilly Japan Co. Ltd. (Hyogo, Japan), AstraZeneca Co. Ltd. (Osaka, Japan), Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan), Chugai Pharmaceutical Co. Ltd. (Tokyo, Japan), and MSD Oncology Co. Ltd. (Tokyo, Japan). T.H. received honoraria from Kyowa-Hakko Kirin and Boehringer Ingelheim. T.H. received research funding from Merck Serono Co. Ltd. (Tokyo, Japan). The remaining authors (Y.T., Y.H., S.H., A.T., T.S., N.M., H.S., N.O., S.A., M.F., Y.K., K.S., A.N., S.M., and T.N.) declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.